Challenges for blood-brain barrier (BBB) screening

Xenobiotica

Volumn 37, Issue 10-11, 2007, Pages 1135-1151

  Jeffrey, P ^a   Summerfield, S G ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Blood brain barrier (BBB); P glycoprotein; Permeability; Tissue binding

Indexed keywords

AMITRIPTYLINE; ANTIHISTAMINIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIMIGRAINE AGENT; ATENOLOL; CARBAMAZEPINE; CENTRAL NERVOUS SYSTEM AGENTS; CHLORPROMAZINE; CLONIDINE; DESIPRAMINE; DOXYLAMINE; FLUOXETINE; FLURBIPROFEN; GABAPENTIN; GLYCOPROTEIN P; GUANFACINE; IBUPROFEN; INDOMETACIN; LABETOLOL; LEVODOPA; LOPERAMIDE; METHADONE; PHENAZONE; RITONAVIR; SALAZOSULFAPYRIDINE; SAQUINAVIR; SUMITRIPTAN; TACRINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

BINDING AFFINITY; BLOOD BRAIN BARRIER; BRAIN TISSUE; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM; DRUG BINDING; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG PENETRATION; DRUG SCREENING; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; MEASUREMENT; NONHUMAN; PERMEABILITY BARRIER; PHYSICAL CHEMISTRY; PROTEIN TRANSPORT; REVIEW; SCREENING;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; CELL MEMBRANE PERMEABILITY; HUMANS; MODELS, NEUROLOGICAL; P-GLYCOPROTEIN; XENOBIOTICS;

EID: 35748977617     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701570285     Document Type: Review

References (74)

1. Abbott JN, Rönnbäck L, Hansson E. 2006. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews: Neuroscience 7:41-53.
2. Al-Awqati Q. 1999. One hundred years of membrane permeability: does Overton still rule? Nature Cell Biology 1:E201-E202.
3. Anthonypillai C, Sanderson RN, Gibbs JE, Thomas SA. 2004. The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. Journal of Pharmacology and Experimental Therapy 308(3):912-920.
4. Bannwarth B, Netter P, Pourel J, Royer RJ, Gaucher A. 1989. Clinical pharmacokinetics of nonsteroidal antiinflammatory drugs in the cerebrospinal fluid. Biomedicine and Pharmacotherapy 43(2):121-126.
5. Becker S, Liu X. 2006. Evaluation of the utility of brain slice methods to study brain penetration. Drug Metabolism and Disposition 34:855-861.
6. Begley DJ, Brightman MW. 2003. Structural and functional aspects of the blood-brain barrier. Progress in Drug Research 61:39-78.
7. Björklund A, Falck B, Hromek F, Owman C. 1969. An enzymic barrier mechanism for monoamine precursors in the newly-forming brain capillaries following electrolytic or mechanical lesions. Journal of Neurochemistry 16(12):1605-1608.
8. Bonati M, Kanto J, Tognoni. 1982. Clinical pharmacokinetics of cerebrospinal fluid. Clinical Pharmacokinetics 7(4):312-335.
9. Boström E, Simonsson US, Hammarlund-Udenaes M. 2006. In vivo blood-brain barrier transport of oxycodone in the rat: Indications for active influx and implications for pharmacokinetics/pharmacodynamics. Drug Metabolism and Disposition 34(9):1624-31.
10. Chen C, Hanson E, Watson JW, Lee JS. 2003. P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. Drug Metabolism and Disposition 31(3):312-318.
11. Chi CH, Dixit BN. 1977. Characterization of (±)-methadone uptake by rat lung. British Journal of Pharmacology 59(4):539-549.
12. Chiou WL. 1996. New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. Journal of Pharmacokinetics and Biopharmacology 24(4):433-442.
13. Clark DE. 2003. In silico prediction of blood-brain barrier permeation. Drug Discovery Today 8:927-933.
14. Cserr HF, Bundgaard M. 1984. Blood-brain interfaces in vertebrates: A comparative approach. American Journal of Physiology 246:R277-R288.
15. Cucullo L, Aumayr B, Rapp E, Janigro D. 2005. Drug delivery and in vitro models of the blood-brain barrier. Current Opinions in Drug Discovery and Development 8(1):89-99.
16. De Boer AG, Gaillard PJ. 2007. Drug targeting to the brain. Annual Reviews in Pharmacology and Toxicology 47:323-355.
17. De Boer AG, Van der Sandt IC, Gaillard PJ. 2003. The role of drug transporters at the blood-brain barrier. Annual Reviews in Pharmacology and Toxicology 43:629-656.
18. De Lange ECM, Ravenstijn PGM, Groenendall D, Van Steeg TJ. 2005. Toward prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic- pharmacodynamic modelling. AAPS Journal 7(3):E532-E543.
19. Doran A, Obach RS, Smith BJ, Hosea NA, Becker S, Callegari E, Chen C, Chen X, Choo E, Cianfrogna J, et al. 2005. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the mdr1a/b knockout mouse model. Drug Metabolism and Disposition 33:165-174.
20. Eytan GD, Kuchel PW. 1999. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. International Reviews in Cytology 90:175-250.
21. Feng MR. 2002. Assessment of blood-brain barrier penetration: in silico, in vitro, and in vivo. Current Drug Metabolism 3:647-657.
22. Fridén M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M.2007. Drug Metabolism and Disposition (in press).
23. Goadsby PJ. 2000. The pharmacology of headache. Progress in Neurobiology 62(5):509-525.
24. Gunn RN, Gunn SR, Cunningham VJ. 2001. Positron emission tomography compartmental models. Journal of Cerebral Blood Flow and Metabolism 21(6):635-652.
25. Gupta A, Chatelain P, Massingham R, Jonsson EN, Hammarlund-Udenaes M. 2006. Brain distribution of cetirizine enantiomers: Comparison of three different tissue-to-plasma partition coefficients: K(p), K(p,u), and K(p,uu). Drug Metabolism and Disposition 34(2):318-323.
26. Henthorn TK, Liu Y, Mahapatro M, Ng KY. 1999. Active transport of fentanyl by the blood-brain barrier. Journal of pharmacology and Experimental Therapeutics 289(2):1084-1089.
27. Hitchcock SA, Pennington LD. 2006. Structure-brain exposure relationships. Journal of Medicine and Chemistry 49:1-25.
28. Höber R. 1936. Membrane permeability to solutes in its relations to cellular physiology. Physiology Review 16:52.
29. Kageyama T, Nakamura M, Matsuo A, Yamasaki Y, Takakura Y, Hashida M, Kanai Y, Naito M, Tsuruo T, Minato N, et al. 2000. The 4F2hc/LAT1 complex transports L-DOPA across the blood-brain barrier. Brain Research 879(1-2):115-121.
30. Kalvass JC, Maurer TS. 2002. Influence of non-specific brain and plasma binding on CNS exposure: Implications for rational drug discovery. Biopharmacology and Drug Disposition 23:327-338.
31. Kalvass JC, Maurer TS, Pollack GM. 2007. Use of plasma and brain unbound fractions to assess the extent of brain distribution of 34 drugs: Comparison of unbound concentration ratios to in vivo P-glycoprotein efflux ratios. Drug Metabolism and Disposition 35:660-666.
32. Katoh M, Suzuyama N, Takeuchi T, Yoshitomi S, Asahi S, Yokoi T. 2006. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport. Journal of Pharmacy Science 95(12):2673-2683.
33. Katritzky AR, Kuanar M, Slavov S, Dobchev DA, Fara DC, Karelson M, Acree WE, Solov'ev VP, Varnek A. 2006. Correlation of blood-brain penetration using structural descriptors. Bioorganic and Medicinal Chemistry 14(14):4888-4917.
34. Kepner GR, editor. (1979). In Cell membrane permeability and transport. [Stroudsberg, PA: Dowden, Hutchins & Ross pp. 29-56].
35. Lentz KA, Polli JW, Wring SA, Humphreys JE, Polli JE. 2000. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharmacy Research (New York) 17:1456-1460.
36. Lin JH. 2004. How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs of Today 40(1):5-22.
37. Liu X, Smith BJ, Chen C, Callegari E, Becker SL, Chen X, Cianfrogna J, Doran AC, Doran SD, Gibbs JP, et al. 2006. Use of a physiologically based pharmacokinetics model to study the time to reach brain equilibrium: An experimental analysis if the role of blood-brain barrier permeability, plasma protein binding, and brain tissue binding. Journal of Pharmacology and Experimental Therapy 313:1254-1262.
38. Loscher W, Frey HH. 1984. Kinetics of penetration of common antiepileptic drugs into cerebrospinal fluid. Epilepsia 25(3):346-352.
39. Luer MS, Hamani C, Dujovny M, Gidal B, Cwik M, Deyo K, Fischer JH. 1999. Saturable transport of gabapentin at the blood-brain barrier. Neurology Research 21(6):559-562.
40. Lundquit S, Renftel M, Brillault J, Fenart L, Cecchelli R, Dehouck MP. 2002. Prediction of drug transport through the blood-brain barrier in vivo: A comparison between two in vitro cell models. Pharmaceutical Research 19:976-981.
41. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW. 2002. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. Journal of Pharmacology and Experimental Therapy 303(3):1029-1037.
42. Mahar Doan KM, Wring SA, Shampine LJ, Jordan KH, Bishop JP, Kratz J, Yang E, Serabjit-Singh CJ, Adkison KK, Polli JW. 2004. Steady-state brain concentrations of antihistaminer in rats: interplay of membrane permeability, p-glycoprotein efflux and plasma protein binding. Pharmacology 72(2):92-98.
43. Martin I. 2004. Prediction of blood-brain barrier penetration: are we missing the point. Drug Discovery Today 9(4):161-162.
44. Maurer TS, Debartolo DB, Tess DA, Scott DO. 2005. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metabolism and Disposition 33:175-181.
45. Mayer S, Maickel RP, Brodie BB. 1959. Kinetics of penetration of drugs and other foreign compounds into cerebrospinal fluid and brain. Journal of Pharmacology and Experimental Therapy 127(3):205-211.
46. Meresse S, Dehouck MP, Delorme P, Bensaid M, Tauber JP, Delbart C, Fruchart JC, Cecchelli R. 1989. Bovine brain endothelial cells express tight junctions and monoamine oxidase activity in long-term culture. Journal of Neurochemistry 53(5):1363-1371.
47. Meyer RP, Gehlhaus M, Knoth R, Volk B. 2007. Expression and function of cytochrome p450 in brain drug metabolism. Current Drug Metabolism 8(4):297-306.
48. Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. 2003. Impact of drug transporter studies on drug discovery and development. Pharmacology Reviews 55(3):425-461.
49. Moriki Y, Suzuki T, Furuishi T, Fukami T, Tomono K, Watanabe J. 2005. In vivo evidence for the efflux transport of pentazocine from the brain across the blood-brain barrier using the brain efflux index method. Journal of Drug Target 13(1):53-59.
50. Narayanan R, Gunturi SB. 2005. In silico ADME modelling: prediction models for blood-brain permeation using a systemic variable selection method. Bioorganic and Medicinal Chemistry 13:3017-3028.
51. Naruhashi K, Tamai I, Li Q, Sai Y, Tsuji A. 2003. Experimental demonstration of the unstirred water layer effect on drug transport in Caco-2 cells. Journal of Pharmacy Science 92(7):1502-1508.
52. Norinder U, Haeberlin M. 2002. Computational approaches to the prediction of the blood-brain distribution. Advanced Drug Delivery Reviews 54:291-313.
53. Ohe T, Sato M, Tanaka S, Fujino N, Hata M, Shibata Y, Kanatani A, Fukami M, Yamakazi M, Chiba M, et al. 2003. Effect of P-glycoprotein mediated efflux on cerebrospinal fluid/plasma concentration ratio. Drug Metabolism and Disposition 31:1251-1254.
54. Overton E. 1899. Vierteljahrsschr. Naturforsch. Ges. Zurich 44:88-135.
55. Pardridge WM. 2007. Blood-brain barrier delivery. Drug Discovery Today 12(1-2):54-61.
56. Parepally JM, Mandula H, Smith QR. 2006. Brain uptake of nonsteroidal anti-inflammatory drugs: Ibuprofen, Flurbiprofen, and Indomethacin. Pharmacology Research 23(5):873-881.
57. Polli JW, Humphreys JE, Wring SA, Burnette TC, Read KD, Hersey A, Butina D, Bertolotti L, Pugnaghi F, Serabjit-Singh C. 2000. A comparison of Madin-Darby canine kidney cells and bovine brain endothelial cells as a blood-brain barrier screen in early drug discovery. In: Balls M, Van Zeller AM, Halder ME, editors. Progress in the reduction, refinement and replacement of animal experimentation. Amterdam: Elsevier. pp. 271-289.
58. Reichal A. 2006. The role of blood-brain barrier studies in the pharmaceutical industry. Current Drug Metabolism 7:183-203.
59. Sieppman J, Siepmann F, Florence AT. 2006. Local controlled drug delivery to the brain: Mathematical modelling of the underlying mass transport mechanisms. International Journal of Pharmaceutics 314:101-119.
60. Singer SJ, Nicolson GL. 1972. The fluid mosaic model of the structure of cell membranes. Science 175(23):720-731.
61. Snyder WS, Cook MJ, Nasset ES, Karhausen LR, Howells GP, Tipton IH. 1975. Report of the Task Force on Reference Man. Oxford: Pergamon.
62. Su Y, Zhang X, Sinko PJ. 2004. Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Molecular Pharmacology 1(1):49-56.
63. Summerfield SG, Jeffrey P. 2006a. In vitro prediction of brain penetration - a case for free thinking? Expert Opinions in Drug Discovery 1(6):595-607.
64. Summerfield SG, Read KD, Begley, Obradovic TT, Hidalgo IJ, Coggon S, Lewis AV, Porter RA, Jeffrey P. 2007. CNS drug disposition: The relationship between in situ brain permeability and brain free fraction. Journal of Pharmacology and Experimental Therapy 322:205-213.
65. Summerfield SG, Stevens AJ, Cutler L, Del Carmen Osuna M, Hammond B, Tang SP, Hersey A, Spalding DJ, Jeffrey P. 2006b. Improving the in vitro prediction of in vivo central nervous system penetration: Integrating permeability, P-glycoprotein efflux, and free fractions in blood and brain. Journal of Pharmacology and Experimental Therapy 316:1282-1290.
66. Sun JJ, Xie L, Liu XD. 2006. Transport of carbamazopine and drug interactions at blood-brain barrier. Acta Pharmacologica scnica. 27(2):244-253.
67. Sung JH, Yu KH, Park JS, Tsuruo T, Kim DD, Shim CK, Chung SJ. 2005. Saturable distribution of tacrine into the striatal extracellular fluid of the rat: Evidence of involvement of multiple organic cation transporters in the transport. Drug Metabolism and Disposition 33(3):440-448.
68. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, Asahi S. 2006. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharmacology Research 23(7):1460-1472.
69. Tran TT, Mittal A, Gales T, Maleeff B, Aldinger T, Polli JW, Ayrton A, Ellens H, Bentz J. 2004. Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. Journal of Pharmacy Science 93(8):2108-2123.
70. Uchino H, Kanai Y, Kim do K, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H. 2002. Transport of amino acid-related compounds mediated by L-type amino acid transporter (LAT1): Insights into the mechanisms of substrate recognition. Molecular Pharmacology 61:729-737.
71. US Food and Drug Agency (USFDA). (2006) Drug interaction studies - study design, data analysis and implications for dosing and labelling. Draft Guidance for Industry, September 2006. Rockville, MD: USFDA (available at: http://www.fda.gov/cder/guidance/index.htm).
72. Van Breemen RB, Li Y. 2005. Caco-2 cell permeability assays to measure drug absorption. Expert Opinion on Drug Metabolism and Toxicology 1(2):175-185.
73. Van de Waterbeemd H, Smith DA, Jones BC. 2001. Lipophilicity in PK design: Methyl, ethyl, futile. Journal of Computer-Aided Molecular Design 15(3):273-286.
74. Wang Q, Rager JD, Weinstein K, Kardos P, Dobson GL, Li J, Hidalgo IJ. 2005. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. International Journal of Pharmacology 288:349-359.